Sorrento Therapeutics, Inc. · OTC:SRNE

Sorrento Therapeutics — Scintilla Pharmaceuticals — Investor Presentation (September 2016)

41 slides from Sorrento Therapeutics's investor presentation, Sep 21, 2016

  1. Slide 1: Corporate Presentation

    Corporate Presentation September 2016

  2. Slide 2: Disclaimer

    Disclaimer NASDAQ:SRNE Scintilla Pharmaceuticals, Inc. (“Scintilla”) is a subsidiary of Sorrento Because actual results are affected by these and other potential risks, con- Therapeutics Inc. (the “Company”), a publicly traded company on the tingencies and uncertainties, the Company cautions investo

  3. Slide 3: Company Overview

    a Sg Company Overview

  4. Slide 4: Vision and Mission

    Vision and Mission Our Vision Our Mission To develop and commercialize a new generation of pain medications To significantly advance treatments targeting moderate to severe pain with and outcomes for pain patients with improved efficacy and reduced risk of innovative, non-opioid pain opioid side-eff

  5. Slide 5: Scintilla Overview

    Scintilla Overview  Scintilla Pharmaceuticals is a majority-owned subsidiary of Sorrento Therapeutics  Announced proposed acquisition of Semnur Pharmaceuticals in August 2016 Portfolio of Two Investigational Product Candidates Spanning Interventional Pain Spectrum  SP-102: first non-opioid, epidu

  6. Slide 6: Investment Highlights

    Investment Highlights  Innovative, Non-opioid Pain Management Portfolio  Large, Established, yet Underserved Target Markets  Worldwide Commercial Rights to All Product Candidates  Strong Proprietary Platform with High Barriers to Entry  Established Reimbursement Access  Two Products with Block

  7. Slide 7: The Right Team to Deliver Long-Term Value

    The Right Team to Deliver Long-Term Value  25+ years of research & development corporate expertise Henry Ji, PhD  Management experience as founder and executive officer of numerous Chairman biotechnology companies  CEO, Sorrento Therapeutics  25+ years of pharma and biotech corporate, commercial

  8. Slide 8: The Pain Market is Expanding and Underserved

    The Pain Market is Expanding and Underserved  Chronic pain affects 116 million, or almost one- in-three, Americans (1) Scintilla Focuses on a Broad Segment of the Pain Market – Costs the United States approximately $560 to $635 billion annually (2) – Nearly 30 million patients suffer from lower bac

  9. Slide 9: Strong Pipeline with Breakthrough Potential

    Strong Pipeline with Breakthrough Potential SP-102 RTX  Potentially the first approved preservative and  Novel non-opioid potential for treatment of intractable surfactant free, steroid indicated for epidural cancer pain administration to treat lumbar radiculopathy  Potentially single injection e

  10. Slide 10: Significant Near Term Clinical Milestone Targets for Scintilla Programs

    Significant Near Term Clinical Milestone Targets for Scintilla Programs  Multiple clinical milestones for all programs expected in the next 12 months – Mid to late stage trials commencing for SP-102 & RTX programs  In addition, potential corporate development milestones may also be achieved with p

  11. Slide 11: SP-102: Innovative Non-opioid Injectable for Chronic Pain

    SP-102: Innovative Non-opioid Injectable for Chronic Pain 11

  12. Slide 12: SP-102 Chronic Pain Opportunity

    SP-102 Chronic Pain Opportunity  Large number of interventional back pain treatment procedures in U.S. (~10M) Large Growing  No interventional prescription pain product approved or in late stage for epidural use in Unsatisfied U.S. Market  Familiarity and rapid acceptance of prescribing physician

  13. Slide 13: FDA Pre-IND Meeting (2014)

    FDA Pre-IND Meeting (2014)  FDA expressed interest in supporting an ESI product with good safety profile  FDA focus on local tox; did not express concerns on systemic tox with API and excipient  FDA stressed marketed injectable steroids are not approved for epidural use but are used extensively a

  14. Slide 14: Fungal Meningitis Outbreak (2012-14)

    Fungal Meningitis Outbreak (2012-14) Meningitis outbreak caused by compounding pharmacy produced steroids for epidural injections, contaminated with Aspergillus fumigatus Infected more than 800 people across 20 states, >60 of whom died By Kurt Eichenwald / April 16, 2015, http://www.newsweek.com/201

  15. Slide 15: Epidural Steroid Injections Are One of the Most Common Medical Procedures

    Epidural Steroid Injections (ESIs) Are One of the Most Common Medical Procedures in the U.S. Common Surgical Procedures in Millions (1) Medicare Overall ESI Injection Volume (2) Epidural Steroid Injections 10,000 All cardiac interventions 7,500 Operations of the GI system 6,000 Knee arthroscopies 4,

  16. Slide 16: SP-102 Market Overview

    SP-102 Market Overview Lumbar Radiculopathy is a subtype of Low Lumbosacral Radicular Pain Market Trends Back Pain characterized by debilitating pain usually requiring medical intervention  Significant Indication Overlap – Spinal Stenosis can be caused by a herniated or bulging disc – Disc degenera

  17. Slide 17: A Focus on Non-narcotic Pain Management Will Drive Growth of ESIs

    A Focus on Non-narcotic Pain Management Will Drive the Growth of Epidural Steroid Injections  Prescription opioid abuse is at epidemic proportions in the U.S.1 Current Problem  Additionally, research shows that opioids do not provide clinically meaningful pain relief in patients with low back pain

  18. Slide 18: Currently Used Steroid Injections and Bolded Warnings

    Chronic Back Pain: Steroid Injections Bolded Warnings Drug Formulation Potential Issues The safety and effectiveness of epidural administration • Methylprednisolone acetate of corticosteroids have not been established and Depomedrol • Contains polyethylene glycol + benzyl corticosteroids are not app

  19. Slide 19: SP-102 Differentiated Product Profile & Positioning

    SP-102 Differentiated Product Profile & Positioning Depo-Medrol SP-102 Kenalog Celestone Important Treatment Attributes (methylprednis- Dexamethasone (Potential) (triamcinolone) (betamethasone) olone) FDA-approved for lumbosacral radicular pain  — — — — Clinical data demonstrating safety and effica

  20. Slide 20: SP-102 Clinical Utility Consistent With Pain Specialists Needs

    SP-102 Clinical Utility of Product Concept is Consistent With Pain Specialists Needs Physicians reacted favorably to the SP-102 product profile, giving the steroid an average score of 6.2 on a favorability scale of 1 – 7 Overall Reaction  Steroid A’s stated duration of effect, non-particulate form,

  21. Slide 21: Lifecycle Management Summary — Opportunities

    Lifecycle Management Summary — Opportunities Physicians indicated there is potential opportunity for spontaneous use of SP-102 in the U.S. outside of lumbar radiculopathy which could represent an additional upside of ~50 – 200%* LR Procedure Volume LR Injection Procedure Forecast 5.5 M Total Procedu

  22. Slide 22: SP-102 Toxicology Program Design Plan

    SP-102 Toxicology Program Design Plan Identical programs in >100 Beagle dogs and Mini-Pigs (each program costs approximately $2m) Multiple arm GLP study using 2 routes:  SD Epidural Control (saline) 1 mL  SD Intrathecal low dose  SD Epidural Placebo 0.4 mL  SD Intrathecal Med Dose  SD Epidural

  23. Slide 23: SP-102 Preclinical Study Results

    SP-102 Preclinical Study Results Hydrodynamic Study Results  Addition of viscosity agent results in a dose dependent prolongation of the residency time of the product within the epidural space  Commercial injectable steroid products (i.e., Kenalog, Depo-Medrol and Decadron) have an epidural reside

  24. Slide 24: SP-102 Clinical Development Plan Overview

    SP-102 Clinical Development Plan Overview Corporate Clinical Strategy is based on a two stage approach…  Stage 1: IND to pivotal Phase 3 decision – Phase 1 / 2 trial in chronic back pain completed dosing – Adequate and well-controlled Phase 3 efficacy trial #1 (USA) – Open-label, long-term safety s

  25. Slide 25: SP-102 Clinical Development: Ongoing Phase 1/2

    SP-102 Clinical Development: Ongoing Phase 1 / 2  An Open-label, Single-arm, Two-period, Fixed Sequential-dose Study to Characterize the Pharmacokinetics, Pharmacodynamics, and Safety Administered by Epidural Injection Compared with Dexamethasone Sodium Phosphate Injection, USP 10 mg Dexamethasone

  26. Slide 26: SP-102 Clinical Development: C.L.E.A.R. Phase 3 Objectives

    SP-102 Clinical Development: C.L.E.A.R. Phase 3 Objectives Corticosteroid Lumbar Epidural Analgesia for Radiculopathy (C.L.E.A.R.)  Evaluate the analgesic effect on leg pain following a single transforaminal epidural injection compared to a single sham injection of placebo saline (0.9% sodium chlor

  27. Slide 27: High Barriers to Entry Protect SP-102

    High Barriers to Entry Protect SP-102 Intellectual Property  Filed IP filing claiming novel formulations (viscosity, dissolution profile, stability, residency time) and method of treating  U.S. Application No. 14/162,625 (“Pharmaceutical Formulation”) filed January 23, 2014 (with priority to U.S.

  28. Slide 28: RTX: First-in-class Therapeutic for Intractable Pain

    RTX: First-in-class Therapeutic for Intractable Pain 28

  29. Slide 29: Product Overview: RTX

    Product Overview: RTX  Ultra potent TRPV1 agonist selectively targeting afferent neurons in chronic pain states  Highly specific: affects only TRPV1 expressing nerves (Aδ and C fibers)  RTX vs. capsaicin Mechanism of 18 Billion Scoville units – Action – Jalapeno 2-5000 – Dorsal horn = > 12,000 ti

  30. Slide 30: RTX Cancer Pain Epidemiology Overview

    RTX Cancer Pain Epidemiology Overview  Intractable cancer pain is a subset of cancer pain usually requiring significant medical intervention  RTX is positioned to replace costly interventional pain management procedures Estimated Patients 2019 18 M Cancer Prevalence  Cancer Pain – 18 million Amer

  31. Slide 31: RTX Breaks Neurogenic Inflammation Cycle

    RTX Breaks Neurogenic Inflammation Cycle: Cancer Pain is the Expected Regulatory Path for First Approval Cancer Pain Tissue Injury Inflammation Focal Neuropathies – Trigeminal – Post Herpetic Syndromes Neurogenic – Phantom Limb – Chronic Regional Pain Inflammation Cycle Organ failure Pain Afferent N

  32. Slide 32: RTX POC: Canine Bone Cancer Pain

    RTX POC: Canine Bone Cancer Pain Preclinical Findings Permanent Reduction In Pain Measured at Week 14 60 No Side Effects As Seen With Opiates Or High Dose NSAIDS Such As n=18 Observational Pain Score 50 VAS (0 to 100 mm) Sedation, Constipation Or Nausea 40 p=0.0001 for all time points Could Sense No

  33. Slide 33: First In-Human Study Confirms Activity

    First In-Human Study Confirms Activity Study Overview Results From First-in Human Studies  A Phase 1 Study of the  Improved pain and increased activity with reduced opioids Intrathecal Administration of  No unexpected toxicities Resiniferatoxin for Treating Severe Refractory Pain  MTD not reache

  34. Slide 34: Switch to Epidural

    Switch to Epidural Untreated Epidural injection into or near the dorsal root ganglion (DRG) for unilateral or diffuse pain Intrathecal Intrathecal injection into the cerebrospinal fluid space (CSF) targeting both DRGs and dorsal Epidural horn neurons Note: Green = Substance P as marker of Afferent n

  35. Slide 35: Human Program Status

    Human Program Status  GMP API completed (3 registration batches) CMC  Commercial supply chain established  Investigational drug product available  Mutagenicity studies completed Tox  Lumbar GLP completed, Pathology and reports ongoing  Cancer Pain – IND planned early 2017 – Epidural MED study

  36. Slide 36: Current Treatment Cost

    Current Treatment Cost Estimated Cost of Patient Controlled Morphine Treatment* Year 2000 Today** Pump Rental, medications, refill charges, and supplies (Per Day) $154 $228 Per Month $4,625 $6,845 6 Month treatment $27,750 $41,070 Top 5 Reasons for Unscheduled Readmission to a Cancer Center (N=1,351

  37. Slide 37: Market Research

    Market Research(1) Initial Price Point Our evaluation suggests that the market will support a potential price range of $15,000 – $30,000 for RTX therapy for pain management in the terminal, intractable pain, cancer patient Based on Key Study Findings  Current coverage of comparator therapies (IT dr

  38. Slide 38: RTX Marketing Opportunities

    RTX Marketing Opportunities Opportunities  Inadequate treatment for cancer patients with intractable pain  Innovative, non-opioid, non-addictive analgesic that works by selectively killing the neurons that are responsible for cancer pain while leaving other neurons intact  Superior efficacy and s

  39. Slide 39: Significant Near Term Clinical Milestones for Scintilla Programs

    Significant Near Term Clinical Milestones for Scintilla Programs  Multiple clinical milestones for all programs expected in the next 12 months – Mid to late stage trials commencing for SP-102 & RTX programs  In addition, potential corporate development milestones may also be achieved with potentia

  40. Slide 40: Financing and Use of Proceeds

    Financing and Use of Proceeds  ~$100 M Private Placement of Common Stock – Fund clinical trials and NDA submissions – Pipeline additions – Key hires across departments – Commercial launch prep – Payment to shareholders related to Semnur acquisition – General corporate purposes 40

  41. Slide 41: Investment Highlights

    Investment Highlights  Innovative, Non-opioid Pain Management Portfolio  Large, Established, yet Underserved Target Markets  Worldwide Commercial Rights to All Product Candidates  Strong Proprietary Platform with High Barriers to Entry  Established Reimbursement Access  Two Products with Block

Scintilla Pharmaceuticals — Investor Presentation (September 2016) on 6ix